Bayer Bets $1.3B On Kumquat Cancer Drug Candidate
Pharmaceutical company Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, on Tuesday announced that they have entered into an exclusive global license and collaboration agreement under which Kumquat will receive...To view the full article, register now.
Already a subscriber? Click here to view full article